Feature June 2019
Sessions & Abstracts
Sessions
Speakers
June 1
Posters
June 1
Poster Board #120a: Education Research and Professional Development
First Author: Danielle Elise Zimmerman, MD, University of Florida Health
Hall A
1:15 P.M. – 4:15 P.M.
June 2
Poster Board #90a: Breast Cancer—Local/Regional/Adjuvant
First Author: Eleftherios P. Mamounas, MD, NRG Oncology, and Orlando Health UF Cancer Center
Hall A
8 A.M. – 11 A.M.
June 3
Poster Board #109b: Gastrointestinal (Colorectal) Cancer
First Author: Thomas J. George, MD, FACP, NRG Oncology, and The University of Florida Health Cancer Center
Hall A
8 A.M. – 11 A.M.
Abstracts
May 31
Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study.
Author(s): Susan R. Rheingold, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Patrick A. Brown, Lia Gore, Naomi J. Winick, William L. Carroll, Stephen Hunger, Elizabeth A. Raetz, Mignon L. Loh, Deepa Bhojwani; Children’s Hospital of Philadelphia, Philadelphia, PA; University of Southern California, Los Angeles, CA; Children’s Oncology Group, Monrovia, CA; University of Florida, Gainesville, FL; Johns Hopkins University School of Medicine, Baltimore, MD; University of Colorado Comprehensive Cancer Center, Aurora, CO; The University of Texas Southwestern Medical Center, Dallas, TX; NYU Langone Medical Center, New York, NY; University of California, San Francisco, San Francisco, CA; New York Univ, Memphis, TN
2:45 P.M. – 5:45 P.M. in S504
Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children’s Oncology Group (COG).
Author(s): Sumit Gupta, Cindy Wang, Elizabeth A. Raetz, Reuven J. Schore, Wanda L. Salzer, Eric Larsen, Kelly W. Maloney, Leonard A. Mattano, William L. Carroll, Naomi J. Winick, Stephen Hunger, Mignon L. Loh, Meenakshi Devidas; Hospital for Sick Children, Toronto, ON, Canada; University of Florida, Gainesville, FL; NYU Langone, New York City, NY; Children’s National Medical Center, Washington, DC; Natl Inst of Health, Olney, MD; Maine Childrens Cancer Program, Scarborough, ME; Children’s Hospital Colorado, Aurora, CO; HARP Pharma Consulting, LLC, Mystic, CT; NYU Langone Medical Center, New York, NY; The University of Texas Southwestern Medical Center, Dallas, TX; Children’s Hospital of Philadelphia, Philadelphia, PA; University of California, San Francisco, San Francisco, CA
2:45 P.M. – 5:45 P.M. in S504
June 1
Simulated patient encounter to assess and improve fellows’ ability to manage chemotherapy infusion reactions.
Author(s): Danielle Elise Zimmerman; University of Florida Health, Gainesville, FL
1:15 P.M. – 4:15 P.M. in Hall A
Poverty and survival in targeted immunotherapy clinical trials.
Author(s): Kira O’Neil Bona, Yimei Li, Lena Winestone, Kelly D. Getz, Yuan-Shung Huang, Brian Fisher, Ami Vijay Desai, Troy Richardson, Matt Hall, Arlene Naranjo, Tara O. Henderson, Richard Aplenc, Rochelle Bagatell; Dana-Farber Cancer Institute/Children’s Hospital Boston, Boston, MA; The Children’s Hospital of Philadelphia, Philadelphia, PA; UCSF Benioff Children’s Hospital and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Chicago Medical Center, Comer Children’s Hospital, Chicago, IL; Children’s Hospital Association, Shawnee Mission, KS; Children’s Hospital Association, Overland Park, KS; Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL; The University of Chicago, Chicago, IL; Children’s Hospital of Philadelphia, Philadelphia, PA
8 A.M. – 11 A.M. in Hall A
Mature results of the LCCC1413 phase II trial of de-intensified chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma.
Author(s): Bhishamjit S. Chera, Robert Amdur, Colette J. Shen, Gaorav P. Gupta, Xianming Tan, Mary Knowles, David N. Hayes, Jared Weiss, Juneko E. Grilley-Olson, Shetal Arvind Patel, Adam M. Zanation, Trevor Hackman, Jose Zevallos, Jeffrey Blumberg, Samip Patel, Mohit Kasibhatla, Nathan Christopher Sheets, Mark Christian Weissler, Wendell Gray Yarbrough, William M. Mendenhall; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Florida, Gainesville, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of North Carolina, Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Division of Medical Oncology, The University of Tennessee Health Science Center, Memphis, TN; University of North Carolina Hospitals, Chapel Hill, NC; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill, NC; Rockingham/UNC Cancer Center, Eden, NC; Rex/University of North Carolina, Raleigh, NC; University of Florida Health Proton Therapy Institute, Jacksonville, FL
1:15 P.M. – 4:15 P.M. in Hall A
4:30 P.M. – 6 P.M. in S100a
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
Author(s): Amir A. Jazaeri, Emese Zsiros, Rodabe Navroze Amaria, Andrew S. Artz, Robert P. Edwards, Robert Michael Wenham, Brian M. Slomovitz, Axel Walther, Sajeve Samuel Thomas, Jason Alan Chesney, Robert Morris, Koji Matsuo, Stephanie Gaillard, Peter Graham Rose, Jesus Garcia Donas, Jacqueline Maria Tromp, Fatemeh Tavakkoli, Huiling Li, Maria Fardis, Bradley J. Monk; The University of Texas – MD Anderson Cancer Center, Houston, TX; Rosewel Park Cancer Institute, Buffalo, NY; University of Chicago Comprehensive Cancer Center, Chicago, IL; Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Miami, Miami, FL; University Hospitals Bristol, Bristol, United Kingdom; University of Florida Health Cancer Center at Orlando Health, Orlando, FL; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Barbara A. Karmanos Cancer Center, Wayne State University, Detroit, MI; Los Angeles County Hospital-University of Southern California, Los Angeles, CA; Johns Hopkins School of Medicine, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Hospital Universitario Madrid Sanchinarro, Madrid, Spain; Academical Medical Center, Amsterdam, Netherlands; Iovance Biotherapeutics, Inc., San Carlos, CA; University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ
8 A.M. – 11 A.M. in Hall A
Results of the dose-finding phase of ARST 1321 from the Children’s Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.
Author(s): Yen-Lin Chen, Aaron R. Weiss, Thomas Scharschmidt, Yueh-Yun Chi, Jennifer M. Black, Edwin Choy, Simon C. Kao, Mark Kayton, Scott H. Okuno, Andrew Ostrenga, R Randall, Stephanie Alicia Terezakis, Eduardo Zambrano, Sheri L. Spunt, Douglas S. Hawkins, Dian Wang; Massachusetts General Hospital, Boston, MA; Maine Medical Center, Portland, ME; Ohio State University, Columbus, OH; Department of Biostatistics, University of Florida, Gainesville, FL; Univ of California San Diego School of Med, Madison, WI; University of Iowa College of Medicine, Iowa City, IA; Palm Beach Children’s Hospital, West Palm Beach, FL; Mayo Clinic, Rochester, MN; University of Mississippi, Jackwon, MS; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; The Johns Hopkins Hospital, Washington, DC; Rocky Mountain Hospital for Children, Denver, CO; Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; Rush University Medical Center, Chicago, IL
8 A.M. – 11 A.M. in Hall A
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results.
Author(s): Thomas J. George, Greg Yothers, Theodore S. Hong, Marcia McGory Russell, Y. Nancy You, William Parker, Samuel A. Jacobs, Peter C. Lucas, Marc Jeffrey Gollub, William Adrian Hall, Lisa A. Kachnic, Namrata Vijayvergia, Norman Wolmark; NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL; NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA; NRG Oncology and Massachusetts General Hospital, Boston, MA; NRG Oncology, and The VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA, Los Angeles, CA; NRG Oncology, and The University of Texas MD Anderson Cancer Center, Houston, TX; NRG Oncology, and McGill University Health Centre, Montreal, QC, Canada; NRG Oncology,and The University of Pittsburgh Cancer Institute, Pittsburgh, PA; NRG Oncology, and University of Pittsburgh School of Medicine, Pittsburgh, PA; NRG Oncology, and Memorial Sloan Kettering Cancer Center, New York, NY; Medical College of Wisconsin, Milwaukee, WI; Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; NRG Oncology, and Fox Chase Cancer Center/ECOG-ACRIN, Philadelphia, PA; NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
3 P.M. – 6 P.M. in Hall B
SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.
Author(s): David S. Hong, Omid S. Tehrani, Howard Safran, Conor Ernst Steuer, Jill Lacy, Matthew H. Taylor, Thomas J. George, Reshma A. Rangwala, Shweta Jain, Leonardo Viana Nicacio, May Thet Cho; The University of Texas MD Anderson Cancer Center, Houston, TX; Karmanos Cancer Inst/Wayne State Univ, Detroit, MI; Brown University Oncology Research Group, Providence, RI; Winship Cancer Institute of Emory University, Atlanta, GA; Smilow Cancer Hospital, Yale University, New Haven, CT; Oregon Health & Science University, Portland, OR; University of Florida Health Cancer Center, Gainesville, FL; Merck & Co., Inc., North Wales, PA; Seattle Genetics, Inc., Bothell, WA; Flatiron Health, New York, NY; Barnes Jewish Hospital, St. Louis, MO
8 A.M. – 11 A.M. in Hall A
ARST1321: Pazopanib neoadjuvant trial in non-rhabdomysarcoma soft tissue sarcomas: A report of major wound complications.
Author(s): Thomas Scharschmidt, Yen-Lin Chen, Dian Wang, Yueh-Yun Chi, Mark Kayton, Joel Sorger, R. Lor Randall, Douglas S. Hawkins, Aaron R. Weiss; Ohio State University, Columbus, OH; Massachusetts General Hospital, Boston, MA; Rush University Medical Center, Chicago, IL; Department of Biostatistics, University of Florida, Gainesville, FL; Palm Beach Children’s Hospital, West Palm Beach, FL; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; Maine Medical Center, Portland, ME
8 A.M. – 11 A.M. in Hall A
Satisfaction of general versus specialized continuity clinic in hematology oncology fellowship training: A survey.
Author(s): Sama Imran Ilyas, Martina Cathryn Murphy, Jennifer Michelle Duff, Julia Lee Close; UFCOM, Gainesville, FL; Shands/Univ of Florida, Gainsville, FL; University of Florida, Dept. of Medicine, Division of Hematology and Oncology, Gainesville, FL; University of Florida, Gainesville, FL
1:15 P.M.- 4:15 P.M. in Hall A
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
Author(s): Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Samuel Thomas, Eric D. Whitman, Omid Hamid, Jose Lutzky, Anna C. Pavlick, Jeffrey S. Weber, James M.G. Larkin, Debora Barton, Lotus Yung, Sam Suzuki, Maria Fardis, John M. Kirkwood; H. Lee Moffitt Cancer Center, Tampa, FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Yale School of Medicine, New Haven, CT; Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR; University of Colorado Comprehensive Cancer Center, Aurora, CO; University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Atlantic Health System Cancer Care, Morristown, NJ; The Angeles Clinic and Research Institute, Los Angeles, CA; Mount Sinai Comprehensive Cancer Center, Miami, FL; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; Royal Marsden NHS Foundation Trust, London, United Kingdom; Iovance Biotherapeutics, Inc., San Carlos, CA; Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
8 A.M. – 11 A.M. in Hall A
1:15 P.M. – 2:45 P.M. in Hall D1
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Author(s): Lauren K. Meyer, Cristina Delgado-Martin, Ritu Roy, Benjamin J. Huang, Tiffaney Vincent, Adam Olshen, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi Devidas, Elizabeth A. Raetz, Robert J. Hayashi, Stuart Winter, Kimberly P. Dunsmore, Stephen Hunger, David T. Teachey, Michelle L. Hermiston; University of California, San Francisco, San Francisco, CA; Children’s Hospital of Philadelphia, Philadelphia, PA; Department of Laboratory Medicine, University of Washington, Seattle, WA; St. Jude Children’s Research Hospital, Memphis, TN; Baylor College of Medicine, Houston, TX; University of Florida, Gainesville, FL; NYU Langone, New York City, NY; Washington University School of Medicine in St. Louis, St. Louis, MO; Children’s Minnesota, Minneapolis, MN; Carilion Children’s, Roanoke, VA
8 A.M. – 11 A.M. in Hall A
A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.
Author(s): Jason Alan Chesney, Jose Lutzky, Sajeve Samuel Thomas, Jorge J. Nieva, Eva Munoz Couselo, Juan Martin-Liberal, Juan Francisco Rodriguez-Moreno, Alex Cacovean, Huiling Li, Maria Fardis, Scott N. Gettinger; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Mount Sinai Medical Center, Miami Beach, FL; University of Florida Health Cancer Center, Windermere, FL; University of Southern California, Los Angeles, CA; Hospital Universitario Vall d’Hebron–PPDS, Barcelona, Spain; ICO Hospitalet, Hospital Duran i Reynals, Barcelona, Spain; Hospital Universitario HM Sanchinarro–CIOCC, Madrid, Spain; Iovance Biotherapeutics, Inc., San Carlos, CA; Yale Cancer Center, New Haven, CT
8 A.M. – 11 A.M. in Hall A
June 2
NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).
Author(s): Sandra M. Swain, Gong Tang, Heather Ann Brauer, David Goerlitz, Peter C. Lucas, Brent T. Harris, Andre Robidoux, Charles E. Geyer, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark; NSABP, and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; NSABP, and University of Pittsburgh, Pittsburgh, PA; NanoString Technologies, Inc., Seattle, WA; Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; NSABP, and The University of Pittsburgh, Pittsburgh, PA; Georgetown University Medical Center, Washington, DC; NSABP, and Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada; NSABP, and Virginia Commonwealth University Massey Cancer Center, Richmond, VA; NSABP, The University of Pittsburgh, and Magee-Womens Hospital, Pittsburgh, PA; NSABP, and The Orlando Health UF Health Cancer Center, Orlando, FL; NSABP, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
8 A.M. – 11 A.M. in Hall A
4:30 P.M. – 6 P.M. in Hall D2
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.
Author(s): Charles E. Geyer, Sibylle Loibl, Priya Rastogi, Sabine Seiler, Joseph P. Costantino, Valentina Nekljudova, Patricia Cortazar, Peter C. Lucas, Carsten Denkert, Eleftherios P. Mamounas, Christian Jackisch, Norman Wolmark; NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond, VA; German Breast Group (GBG) and Centre for Haematology and Oncology Bethanien, Frankfurt, Neu-Isenburg, Germany; NSABP, The University of Pittsburgh, and Magee-Womens Hospital, Pittsburgh, PA; German Breast Group (GBG), Neu-Isenburg, Germany; NSABP Foundation and The University of Pittsburgh, Pittsburgh, PA; Genentech, Inc., San Francisco, CA; NSABP, and The University of Pittsburgh, Pittsburgh, PA; Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg, Marburg, Germany; NSABP, and The Orlando Health UF Health Cancer Center, Orlando, FL; Sana Klinikum Offenbach GmbH, Offenbach, Germany; NSABP, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
8 A.M. – 11 A.M. in Hall A
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
Author(s): William M. Sikov, Mei-Yin Polley, Erin Twohy, Charles M. Perou, Baljit Singh, Donald A. Berry, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia X. Ma, Charles S. Kuzma, Eleftherios P. Mamounas, Mehra Golshan, Jennifer Ruth Bellon, Deborah E. Collyar, Olwen Mary Hahn, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey; Women and Infants Hospital of Rhode Island, Providence, RI; Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of North Carolina at Chapel Hill, Chapel Hill, NC; New York University Langone Medical Center, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; City of Hope, Duarte, CA; Mount Sinai Medical Center, New York, NY; Washington University School of Medicine in St. Louis, St. Louis, MO; First Health of the Carolinas Cancer Ctr, Pinehurst, NC; NSABP, and The Orlando Health UF Health Cancer Center, Orlando, FL; Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA; Patient Advocates Rsch, Danville, CA; University of Chicago Medical Center, Chicago, IL; American Society of Clinical Oncology, Alexandria, VA; University of North Carolina, Chapel Hill, NC
8 A.M. – 11 A.M. in Hall A
Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Author(s): Andreas Schneeweiss, Sibylle Loibl, Eleftherios P. Mamounas, Gunter von Minckwitz, Max S. Mano, Michael Untch, Chiun-Sheng Huang, Priya Rastogi, Pier Franco Conte, Veronique D’hondt, Andres Redondo, Ljiljana Stamatovic, Herve R. Bonnefoi, Hugo Raul Castro Salguero, Hans Holger Fischer, Tanya A. Wahl, Chunyan Song, Steven Blotner, Peter Trask, Charles E. Geyer; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; German Breast Group (GBG) and Centre for Haematology and Oncology Bethanien, Frankfurt, Neu-Isenburg, Germany; NSABP, and The Orlando Health UF Health Cancer Center, Orlando, FL; GBG, Neu-Isenburg, Germany; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil; AGO-B and HELIOS Klinikum Berlin-Buch, Berlin, Germany; National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; NSABP Foundation and University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Padova, Padova, Italy; Institut Régional du Cancer de Montpellier, Montpellier, France; Hospital Universitario La Paz-IdiPAZ, Madrid, Spain; Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; Institut Bergonié Unicancer and Bordeaux University, Bordeaux, France; Grupo Medico Angeles, Guatemala City, Guatemala; GBG and Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany; Swedish Cancer Institute, Issaquah, WA; Genentech, Inc., South San Francisco, CA; NSABP, and Virginia Commonwealth University Massey Cancer Center, Richmond, VA
8 A.M. – 11 A.M. in Hall A
4:30 P.M. – 6 P.M. in Hall D2
PIK3CA mutation as a prognostic factor in HPV-associated oropharynx cancer.
Author(s): Brian T. Beaty, Gaorav Gupta, Colette J. Shen, Robert J Amdur, Jared Weiss, Juneko E. Grilley-Olson, Shetal Arvind Patel, Adam M. Zanation, Trevor Hackman, Brian Thorp, Jeffrey Blumberg, Samip Patel, Mark Christian Weissler, Wendell Gray Yarbrough, Nathan Christopher Sheets, Joel S. Parker, Neil Hayes, William M. Mendenhall, Roi Dagan, Bhishamjit S. Chera; University of North Carolina, Chapel Hill, NC; University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Radiation Oncology, University of Florida, Gainesville, FL; University of North Carolina Hospitals, Chapel Hill, NC; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Otolaryngology, University of North Carolina School of Medicine, Chapel Hill, NC; Rex/University of North Carolina, Raleigh, NC; Lineberger Comprehensive Center. Department of Genetics. University of North Carolina, Chapel Hill, NC; University of Tennessee, Germantown, TN; University of Florida Health Proton Therapy Institute, Jacksonville, FL; University of Florida Proton Therapy Institute, Jacksonville, FL
8 A.M. – 9:30 A.M. in E450
Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.
Author(s): Chieko Michikawa, Pedro A. Torres-Saavedra, Natalie L. Silver, Paul M. Harari, Merrill S. Kies, David Ira Rosenthal, Quynh-Thu Le, Richard C. Jordan, Dzifa Yawa Duose, Saradhi Mallampati, Sanchit Trivedi, Rajyalakshmi Luthra, Ignacio Ivan Wistuba, Olivier Lichtarge, Robert Leonard Foote, Upendra Parvathaneni, David N. Hayes, Curtis R. Pickering, Jeffrey Myers; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Department of Otolaryngology-Head and Neck Surgery, University of Florida, Gainesville, FL; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA; NRG Oncology Biospecimen Bank, University of California, San Francisco, San Francisco, CA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Molecular and Human Genetics, Pharmacology, and Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX; Department of Radiation Oncology, Mayo Clinic, Rochester, MN; Radiation Oncology Center, University of Washington Medical Center, Seattle, WA; Division of Medical Oncology, The University of Tennessee Health Science Center, Memphis, TN
8 A.M. – 9:30 A.M. in E450
A revised Children’s Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.
Author(s): Meredith Irwin, Arlene Naranjo, Susan Lerner Cohn, Wendy B London, Julie M Gastier-Foster, John M. Maris, Rochelle Bagatell, Julie R. Park, Michael D. Hogarty; The Hospital for Sick Children, Toronto, ON, Canada; Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL; The University of Chicago Medicine, Chicago, IL; Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; Nationwide Children’s Hospital, Columbus, OH; Children’s Hospital of Philadelphia, Philadelphia, PA; Seattle Children’s Hospital and University of Washington School of Medicine, Seattle, WA
8 A.M. – 11 A.M. in S504
June 3
Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children’s Oncology Group (COG) and NRG Oncology.
Author(s): Aaron R. Weiss, Yueh-Yun Chi, Yen-Lin Chen, Edwin Choy, Jessica L. Davis, Julie Fanburg-Smith, Douglas S. Hawkins, Mark Kayton, Lynn Million, Scott H. Okuno, Andrew Ostrenga, R. Lor Randall, Thomas Scharschmidt, Joel Sorger, Sheri L. Spunt, Jing Tian, Stephanie Alicia Terezakis, Dian Wang, Eduardo Zambrano, Jennifer O. Black; Maine Medical Center, Portland, ME; Department of Biostatistics, University of Florida, Gainesville, FL; Massachusetts General Hospital, Boston, MA; Oregon Health & Science University, Portland, OR; Penn State Hershey Cancer Institute, Hershey, PA; Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; Palm Beach Children’s Hospital, West Palm Beach, FL; Stanford University School of Medicine, Stanford, CA; Mayo Clinic, Rochester, MN; University of Mississippi, Jackwon, MS; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Ohio State University, Columbus, OH; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; COG, Gainesville, FL; The Johns Hopkins Hospital, Washington, DC; Rush University Medical Center, Chicago, IL; Rocky Mountain Hospital for Children, Denver, CO; Children’s Hospital Colorado, Aurora, CO
8 A.M. – 11 A.M. in E450
Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.
Author(s): Thomas J. George, Greg Yothers, James J. Lee, Melvin Deutsch, Samuel A. Jacobs, Carmen Joseph Allegra, Norman Wolmark; NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL; NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA; NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; NRG Oncology, and UPMC Dpt Radiation Oncology, Pittsburgh, PA; NRG Oncology,and The University of Pittsburgh Cancer Institute, Pittsburgh, PA; NRG Oncology, and The University of Florida, Gainesville, FL; NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
8 A.M. – 11 A.M. in Hall A
Blood-based next-generation sequencing analysis of neuroendocrine tumors.
Author(s): Walid Labib Shaib, Ali Roberts, Katerina Mary Zakka, Mehmet Akce, Christina Wu, Olatunji B. Alese, Bassel F. El-Rayes, Pashtoon Murtaza Kasi, Jason Scott Starr; Winship Cancer Institute, Emory University, Atlanta, GA; Guardant Health, Inc., Redwood City, CA; Winship Cancer Institute of Emory University, Atlanta, GA; Winship Cancer Institute, Atlanta, GA; Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; Mayo Clinic, Jacksonville, FL; University of Florida Health Cancer Center, Jacksonville, FL
8 A.M. – 11 A.M. in Hall A
Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.
Author(s): Pashtoon Murtaza Kasi, Saivaishnavi Kamatham, Dorin Colibaseanu, Amit Merchea, Faisal Shahjehan, Jason Scott Starr, Kabir Mody; Mayo Clinic, Jacksonville, FL; University of Florida Health Cancer Center, Jacksonville, FL
8 A.M. – 11 A.M. in Hall A
Publication Only
Multiplexed digital PCR for detection of HPV in tissue samples from oropharyngeal cancer patients.
Author(s): Sunil Kumar, Bhishamjit S. Chera, Brian Beaty, David Marron, Stuart Jefferys, Robert Amdur, Nathan Sheets, Roi Dagan, David N. Hayes, Jared Weiss, Juneko E. Grilley-Olson, Adam M. Zanation, Trevor Hackman, Jeffrey Blumberg, Samip Patel, Mark Christian Weissler, Joel S. Parker, Xianming Tan, William M. Mendenhall, Gaorav Gupta; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Florida, Gainesville, FL; UNC Rex Hospitals, Raleigh, NC; University of Florida, Jacksonville, FL; Division of Medical Oncology, The University of Tennessee Health Science Center, Memphis, TN; University of North Carolina Hospitals, Chapel Hill, NC; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill, NC; Lineberger Comprehensive Center. Department of Genetics. University of North Carolina, Chapel Hill, NC; University of North Carolina, Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of Florida Health Proton Therapy Institute, Jacksonville, FL
DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.
Author(s): Rohit Bishnoi, Young-Rock Hong, Chintan Shah, Azka Ali, William Paul Skelton, Jinhai Huo, Nam H. Dang, Long H. Dang; University of Florida, Gainesville, FL; University Of Florida, Gainesville, FL; University of Florida College of Medicine Department of Internal Medicine, Gainesville, FL; Ochsner Medical Center, Baton Rouge, LA
DPP4 inhibitors as novel agents in improving survival in patients with prostate cancer: A SEER-Medicare study.
Author(s): Chintan Shah, Young-Rock Hong, Rohit Bishnoi, azka ali, William Paul Skelton, Long H. Dang, Jinhai Huo, Nam H. Dang; University Of Florida, Gainesville, FL; University of Florida, Gainesville, FL; University of Florida College of Medicine Department of Internal Medicine, Gainesville, FL; Ochsner Medical Center, Baton Rouge, LA
Colorectal cancer in young patients: An institutional experience.
Author(s): Wissam Hanayneh, Yu Wang, Thomas J. George, Miles Cameron, Sanda Tan, Atif Iqbal, Thomas Read, Carmen Joseph Allegra, Hiral D. Parekh; University of Florida, Gainesville, FL; University of Florida Health Cancer Center, Gainesville, FL; NSABP Foundation, and The University of Florida, Gainesville, FL
Role of adjuvant chemotherapy in small (≤5 mm) node-negative and hormone receptor-negative breast cancer.
Author(s): Samip R. Master, Neelakanta Dadi, Chintan Shah, Gary Von Burton, Runhua Shi; Louisiana State University Health Sciences Center, Shreveport, LA; Louisiana State University Health Sciences Center, New Orleans, LA; University Of Florida, Gainesville, FL; LSU Health Sciences Center, Shreveport, LA
Enrollment disparities in cancer clinical trials: A single institution experience.
Author(s): Ariel Perez Perez, Nawid Mohammad Sarwari, Terra Warner, Liqiang Ni, Danny Landau; UF Health Cancer Center / Orlando Health, Orlando, FL; Orlando Health, Orlando, FL; UF Health Cancer Center at Orlando, Orlando, FL; University of Central Florida, Orlando, FL; University of Florida Health Cancer Center–Orlando Health, Orlando, FL
Tumor stroma percentage (TSP) and intrinsic subtypes in stage II/III colon cancer: NRG Oncology/NSABP C-07 trial.
Author(s): Rim S Kim, Patrick G Gavin, Soonmyung Paik, Carmen Joseph Allegra, Samuel A. Jacobs, Katherine L. Pogue-Geile, Peter C. Lucas; NRG Oncology, Pittsburgh, PA; NRG Oncology, and Yonsei University College of Medicine, Seoul, South Korea; NRG Oncology, and The University of Florida, Gainesville, FL; NSABP/NRG Oncology, Pittsburgh, PA; NRG Oncology, and University of Pittsburgh School of Medicine, Pittsburgh, PA
Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.
Author(s): Brian Hemendra Ramnaraign, Brittany Kayla Rogers, Susan P. McGorray, Michele Sugrue, Hemant S. Murthy, John W. Hiemenz, Jack W. Hsu, John R. Wingard, Nosha Farhadfar; University of Florida, Gainesville, FL; University of Florida Health Cancer Center, Gainesville, FL
The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER).
Author(s): Andre C. Schuh, Yan Li, Max S. Topp, Xinke Zhang, Paul Cannell, Herve Dombret, Johan Maertens, Anthony Selwyn Stein, Janet Franklin; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Florida, Department of Pharmaceutical Outcomes & Policy, Gainesville, FL; Medizinische Klinik und Poliklinik II, Würzburg, Bayern, Germany; Amgen Inc., Thousand Oaks, CA; Department of Health, Western Australia, Perth, Australia; Université Diderot, Paris, France; UZ Leuven, Leuven, Belgium; Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA
The internet bias toward nontraditional first line prostate cancer treatments.
Author(s): Danny Landau, Alec Landau; University of Florida Health Cancer Center–Orlando Health, Orlando, FL; Orlando Health UF Health Cancer Center, Orlando, FL
Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.
Author(s): Saivaishnavi Kamatham, Dorin Colibaseanu, Amit Merchea, Faisal Shahjehan, Jason Scott Starr, Kabir Mody, Pashtoon Murtaza Kasi; Mayo Clinic, Jacksonville, FL; University of Florida Health Cancer Center, Jacksonville, FL
A single-center retrospective analysis of the effect of Radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer.
Author(s): William Paul Skelton, Samantha Welniak Dibenedetto, Sarah Pang, Kelsey Pan, Jacob Barish, Adaeze Nwosu-Iheme, Long H. Dang; University of Florida, Gainesville, FL; Ochsner Medical Center, Baton Rouge, LA
Functional personalized oncology to determine drug sensitivity in cholangiocarcinoma.
Author(s): Ali Zarrinpar, Un Bi Kim, Carla Grandori, Franz Schaub, Rachele Rosati; University of Florida, Gainesville, FL; SEngine Precision Medicine, Seattle, WA